Log in or Sign up for Free to view tailored content for your specialty!
Neuromuscular Disease News
Accelerometers may be reliable tool for measuring ALS disease progression
Wearable accelerometers may be a reliable tool to track disease progression in patients with amyotrophic lateral sclerosis, researchers wrote in The Lancet.
FDA approves Ingrezza sprinkle capsules for tardive dyskinesia, Huntington’s chorea
The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive dyskinesia, according to a press release from the manufacturer.
Log in or Sign up for Free to view tailored content for your specialty!
Combination ALS therapeutic nonsuperior to placebo in phase 3 clinical trial
DENVER — A combination therapeutic for amyotrophic lateral sclerosis was nonsuperior to placebo over 48 weeks in a phase 3 clinical trial, according to a presenter at the American Academy of Neurology annual meeting.
VIDEO: Troriluzole alters trajectory of spinocerebellar ataxia
DENVER — Four studies presented at the American Academy of Neurology annual meeting show improvements in patients with spinocerebellar ataxia who take troriluzole.
FDA clears investigational new drug application for Fragile X treatment
The FDA has cleared an investigational new drug application for a small molecule therapeutic to treat those with Fragile X syndrome, according to the manufacturer.
IV efgartigimod improves daily functionality in generalized myasthenia gravis
DENVER — Treatment with IV efgartigimod improved functionality for individuals with acetylcholine receptor-positive generalized myasthenia gravis, according to a poster from the American Academy of Neurology annual meeting.
Amylyx pulls ALS drug Relyvrio from market in US, Canada
Amylyx Pharmaceuticals Inc. announced Relyvrio, its amyotrophic lateral sclerosis therapeutic, will be removed from the market in the United States and Canada, effective immediately.
Intra-molecular compound advanced as potential disease-modifying therapy for ALS
A Cincinnati-based life sciences company announced that one of its development candidates, ASHA-624, will be advanced as a potential disease modifying therapy for amyotrophic lateral sclerosis.
Multiple Sclerosis Awareness Month: Latest research, treatments from ACTRIMS 2024
March is Multiple Sclerosis Awareness Month, a time to improve knowledge of and highlight the growing treatment options for progressive types of this degenerative disease.
Partnership aims to commercialize brain-computer interface technology
A Boston-area developer of brain-computer interface technology and a Canadian biotech firm have announced a collaboration to globally commercialize the former’s brain health tools.
-
Headline News
Study: Young patients hesitant to tell providers information their parents might see
November 06, 20242 min read -
Headline News
Q&A: Adults may know their risk for COPD with blood test
November 07, 20243 min read -
Headline News
CMS increases payment for dialysis facilities, includes oral-only drugs in the bundle
November 08, 20242 min read
-
Headline News
Study: Young patients hesitant to tell providers information their parents might see
November 06, 20242 min read -
Headline News
Q&A: Adults may know their risk for COPD with blood test
November 07, 20243 min read -
Headline News
CMS increases payment for dialysis facilities, includes oral-only drugs in the bundle
November 08, 20242 min read